Hodgkin's Lymphoma | Lymphoid Leukemia | Non-Hodgkin's Lymphoma

Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

Volunteers
Health Professionals

What is the purpose of this trial?

Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Ria Syam

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Iris Isufi, MD
Associate Professor of Medicine (Hematology); Co-Director Adult CAR T-Cell Therapy Program, Hematology; Co-Leader, Cellular Therapy Clinical Research Team, Yale Cancer Center; Co-Chair, Cellular Therapy (CT)-SAFE Committee, Yale Cancer Center

Sub-Investigators

Last Updated
10/10/2024
Study HIC
#2000025634